Delving into the Latest Updates on FL-386 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

Lipase

Mechanism

Lipase inhibitors

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Obesity

Originator Organization

Taiho Pharmaceutical Co., Ltd.

Active Organization-

Inactive Organization

Taiho Pharmaceutical Co., Ltd.

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC18H26O4S

InChIKeyRLVLLBHWAQWLKL-WKILWMFISA-N

CAS Registry84856-18-8

A newly synthesized inhibitor of pancreatic lipase and micelle formation, FL-386, was administered at a dose of 400 mg (in the diet, for seven consecutive days) to nine healthy adult volunteers, and changes in faecal mass, frequency of defaecation, and properties of the stools were observed. High performance liquid chromatography and gas-liquid chromatography were used to analyse the faeces for short-chain carboxylic acids, neutral sterols, bile acids, fats and hydroxyfatty acids. FL-386 had little effect on the amounts and composition of short-chain carboxylic acids, neutral sterols, and bile acids excreted, nor did it produce changes in the composition of fatty acids, or the percentages of hydroxyfatty acids in the stool. However, in those patients treated with FL-386, the faecal mass was increased, and stools were softer and contained increased amounts of fatty acids. The compound did not produce particularly fatty stools. It was concluded that FL-386 induces slight disturbance in the digestion and absorption of dietary lipids.

01 Jan 1988·Journal of Chromatography B: Biomedical Sciences and Applications

Determination of a new hypolipidemic agent, 2-(trans-4-isobutylcyclohexyl)-2-oxoethyl benzenesulphonate, and its metabolite by high-performance liquid chromatography and gas chromatography—mass fragmentography in human biological materials

Article

Author: Madoka Maniwa ; Yukihiko Umeno ; Teruyoshi Marunaka

The title drug (FL-386) and its primary metabolite, benzenesulfonic acid, were determined in human blood, urine, and feces by HPLC with a Shim-pak CLC ODS column, a mobile phase of MeOH-H₂O (75:25), and detection at 220 nm, and by gas chromatog.-mass fragmentog., resp..The detection limits were 0.1 μg FL-386/mL in all samples, and 1 ng/mL in plasma or urine and 5 ng/mL feces for the metabolite.

100 Deals associated with FL-386

Login to view more data